Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Pinebridge Investments L.P.

Pinebridge Investments L.P. trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 14.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,300 shares of the medical equipment provider's stock after selling 13,269 shares during the period. Pinebridge Investments L.P.'s holdings in Zimmer Biomet were worth $8,165,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ZBH. Dodge & Cox lifted its position in shares of Zimmer Biomet by 12.0% in the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock valued at $2,019,480,000 after acquiring an additional 2,044,645 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Zimmer Biomet by 1.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock valued at $1,559,147,000 after acquiring an additional 176,337 shares in the last quarter. Van ECK Associates Corp boosted its holdings in shares of Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock valued at $417,814,000 after purchasing an additional 218,688 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Zimmer Biomet by 398.7% during the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after purchasing an additional 2,796,372 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Zimmer Biomet in the fourth quarter worth about $216,223,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Raymond James decreased their price objective on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Truist Financial reiterated a "hold" rating and set a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Barclays reduced their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Monday, February 10th. JMP Securities reaffirmed a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, Royal Bank of Canada decreased their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $124.15.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.70% of the company's stock.

Zimmer Biomet Stock Down 0.0 %

NYSE ZBH traded down $0.04 on Friday, reaching $101.46. 1,661,962 shares of the stock traded hands, compared to its average volume of 1,669,704. Zimmer Biomet Holdings, Inc. has a 12 month low of $93.10 and a 12 month high of $123.96. The company has a market cap of $20.07 billion, a price-to-earnings ratio of 22.80, a PEG ratio of 1.95 and a beta of 0.84. The company has a fifty day moving average price of $105.81 and a 200-day moving average price of $106.61. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the company earned $2.20 earnings per share. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.95%. Zimmer Biomet's dividend payout ratio is currently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.